Evotec, Celgene partner in targeted protein degredation deal

Celgene Corp. (NASDAQ:CELG) partnered with Evotec AG (Xetra:EVT) to identify difficult to track drug targets, focusing on targeted protein degradation, using Evotec’s Panomics platform. Evotec will receive an undisclosed upfront payment and is eligible for milestones and royalties. Celgene will hold exclusive rights to all programs developed under the deal...